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Abstract
Alzheimer’s disease is a neurodegenerative disorder that is the 6th leading cause of death in the United States. More than
5.5 million People over the age of 65 are currently diagnosed with Alzheimer’s disease with predictions of 13.8 million to
be diagnosed by the year 2050 (Sultana, et al., 2013) (Hebert,Weuve, Scherr, & Evans, 2013).With few treatments available,
scientists are desperately looking for a solution to this growing epidemic. Creutzfeldt-Jakob disease is also a neurodegenerative disorder, but with a far less prevalence of only 4.6 persons per million per year. It was discovered that Alzheimer’s
and Creutzfeldt-Jakob disease share many pathophysiological mechanisms with each other. Being that both of these
illnesses are currently incurable, a thorough critical analysis of mechanisms and potential treatments were preformed to
ascertain if knowledge in one disorder can help find a cure for the other. With the strong relationship between these two
disorders, it was found that many treatments intended for one illness had positive results for the other (some with slight
modifications). The discovery of this correlation improved scientist’s knowledge of the pathological mechanism of these
ailments along with finding new and creative ways for treatment. Experiments geared towards the relationship between
Alzheimer’s and Creutzfeldt-Jakob disease has brought researchers closer to finding a cure for several neurodegenerative
disorders.
Introduction
Alzheimer’s Disease (AD) and Creutzfeldt-Jacob Disease (CJD)
are two disorders characterized by their neurodegenerative
symptoms. These ailments are both considered forms of dementia consisting of phenotypes portraying a patient’s loss of memory, mood irregularities, paranoia, and several other neurological
symptoms. Physiologically, AD is characterized by its Amyloid-β
and Tau protein plaques while CJD is characterized by its prevalence of misfolded prion proteins throughout the brain. Albeit
these two diseases are believed to have different modes of physiological symptoms, they share many similarities with each other
and other neurodegenerative disorders causing many scientists
to theorize a possible correlation between their mechanisms. It is
partly due to these similarities that physicians often misdiagnose
various dementia relating disorders as either CJD or AD. In a
study of 304 autopsies that showed no prion disease prevalence,
71 (23%) of the patients had Sporadic CJD (a variant form of CJD
characterized by unknown cause) as a possible diagnosis in their
medical records (Chitravas, et al., 2011). Another study showed
that “between 12% and 23% of patients diagnosed with AD do
not have sufficient AD pathology at autopsy to account for the
presence of dementia (“misdiagnosed”) (Gaugler, et al., 2013).”
Due to the vast likeness between many dementias, there has not
been a definitive noninvasive procedure to precisely diagnose disorders such as CJD and AD (Mayo Clinic Staff, 2014).
Although AD and CJD share similarities, their prevalence in
American society is far dissimilar. AD is the 6th leading cause
of death with an estimated 5.5 million people over the age of
65 who are afflicted with this neurodegenerative disorder in the
United States (Sultana, et al., 2013). CJD on the other hand, displays a prevalence of a mere 4.6 cases per million people over the
age of 60 ( Centers for Disease Control and Prevention , 2014).
This is far fewer than the thousands of people who are diagnosed
each year with AD.

Despite the rarity of CJD, numerous research endeavors have
been conducted in understanding this prion disease. One explanation for this attention is due to the unique properties of a
prion; a protein which acts as an infectious pathogen misfolding
other proteins into additional prions (Wadsworth, et al., 2008).
What is more surprising is that prions have been found in patients diagnosed with AD (Armstrong, et al., 2005). This would
further suggest a possible correlation between pathogenic mechanisms of AD and CJD. Today various treatments for AD and CJD
are currently in clinical trials to try to treat these incurable diseases. If there is a correlation between pathological mechanisms,
further research into one of these neurodegenerative disorders
can help scientists better understand and treat the other.
The purpose of this research article will be to define and explain
the physical and physiological symptoms and mechanisms of AD
and CJD, suggest possible correlations between the two, discuss
current treatments, and lastly, the different forms of possible
treatments will be compared to postulate a possible venue to
determine if they would be effective to treat the other illness.

Methods
Several online databases were used such as: Google Scholar,
PubMed, and Jstor which were accessed through Touro College’s
online library. Additional references were gleaned from papers
found in these databases

Discussion
CJD Pathophysiology
CJD is quite unique due to its pathophysiological mechanism.
While most infectious diseases are viral or bacterial based, CJD
uses a prion to spread its illness. In actuality, every individual contains Prion Proteins (PrPc) which are believed to be necessary
for normal synaptic function (Collinge, et al., 1994). It is when
this human-coded PrPc is post-translated and converted into
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an abnormal isoform (PrPsc) that it starts to exhibit pathological tendencies. Data suggests that this abnormal protein is the
main, if not the solitary, component of the transmissible disease
(Wadsworth, et al., 2008). Once the PrPsc comes into contact
with a normal PrPc, it causes a transmutation of residue 129
turning it into a pathological agent. This replaces the amino acid
by residue 129 on the protein into either valine or methionine.
Whereas many scientists agree that the prion protein is the main
constituent of CJD, there is debate over the validity of this claim.
Manuelidis, et al (2007), argue that the abnormal PrPsc form of
the prion protein is a result, not the cause, of CJD. They claim
that a 25 nm virus is the cause of the abnormal prion isoform.
They discredit the long accepted hypothesis, that prions are the
sole pathological constituents of CJD, for several reasons. Studies
show, “high PrP-expressing transgenic brains, as well as abnormal
recombinant PrPs, have failed to show significant or reproducible
infectivity”. Additionally, the authors claim that after several decades of research, scientists found no “infectious conformation”
of PrPsc. Furthermore, sheep with scrapie showed signs of these
25 nm viruses while uninfected controls showed no prevalence
of these particles. These facts caused many researches to share
doubt on the prion-only hypothesis.
Another theory with tangible evidence suggests a different mode
of pathological mechanism. Several studies suggest that non-proteinaceous cofactors are needed to facilitate the infectious properties of PrPsc, hypothesizing that prions work via multiple components in order to function (Deleault, et al., 2012). While there
are studies that show that purified PrPcs which were folded
chemically into amyloid fibrils showed little infectivity, a combination of PrPc, liver RNA, and synthetic 1-palmitoyl-2-oleoyl-phosphatidylglycerol (POPG) lipid molecules facilitated the production of authentic infectious prions. The contrasts between the
infectivity of PrPc obtained from amyloid fibrils and from PrPc
combined with lipids and RNA support this theory (see figure
1). However, further study should be conducted to determine
whether the cofactors are required for pathology or are merely
a catalyst for a slow progressive disorder (Supattapone, 2010).
These experiments cast doubt on the viral hypothesis of prion
disease. If viruses were the cause of prion pathology, why were
scientists able to reproduce CJD symptoms with only PrPc and
various cofactors?
There are several ways for an individual to contract CJD. Factors
include ingestion of prion-infected tissue, contamination during a
procedure (most commonly a contaminated tissue transplant or
equipment), inheritance of a mutation in the PrPc gene (PRNP),
or sporadically (no apparent cause). When tissue infected with
abnormal prions is ingested, such as meat from a cow infected
with Bovine Spongiform Encephalopathy (BSE, also known as Mad
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Figure 1
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Extra ingredients:Two different biochemical protocols yield recombinant PrPc
with different infectivity. (Left) Minimally infectious amyloid ﬁbrils are formed
by incubating recombinant PrPc with chemical denaturants. (Right) Mixing
recombinant PrPc with phospholipid and RNA produces highly infectious prions.
(Supattapone, 2010)

Cow Disease), a variant form of CJD is contracted named variant CJD (vCJD). Contamination via a procedure causes a form
of CJD termed Iatrogenic CJD while a genetic mutation that is
inherited is called Genetic CJD. CJD that is acquired sporadically
is referred to as Sporadic CJD (sCJD) (Wadsworth, et al., 2008).
According to Wadsworth et al (2008), approximately 85% of cases
with CJD occur as the sporadic variant (sCJD) while 15% are associated with a pathogenic mutation in the PRNP gene (Genetic
CJD). Wadsworth further explains that the rare iatrogenic form
of CJD occurs most frequently due to the transmission of prions
via contaminated growth hormones from cadavers or by implementation of contaminated dura mater grafts. Additionally, it has
been speculated that iatrogenic CJD can be transmitted via blood
transfusions although it is extremely rare (Ricketts, et al., 1997).
Prion disease prevalence has been tied to vCJD in the United
Kingdom by the consumption of cattle with BSE. Another unique
variant of CJD, named Kuru, is found in the Eastern Highlands of
Papua New Guinea where members of the community would
feast on the deceased relatives as a sign of respect and grief. From
the community in Papua, scientist discovered that the incubation
period of individuals infected with PrPsc could exceed 50 years
(Wadsworth, et al., 2008).
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Individuals with CJD often exhibit phenotypical signs of dementia and various other neurodegenerative symptoms. The primary indication of CJD is the observation of sponge-like holes
in a person’s brain giving the appearance of a sponge; for this
reason, many scientists refer to prion diseases as transmissible
spongiform encephalopathies (TSEs). Additionally, patients have
been known to portray feelings of anxiety, depression as well
difficulties of cognition such as impaired thinking, memory loss,
personality changes, insomnia and difficulty speaking. Blurred vision, difficulty swallowing and sudden jerky movements are also
typical signs of CJD. As the progression of the illness takes its
course, cognitive phenotypical symptoms worsen. A majority of
individuals lapse into a coma and eventually die due to cardiac
arrest, respiratory failure, or an infectious pathogen. The duration of duress is typically 7 months for classical CJD and 12-14
months for variant CJD; however, patients have been known to
live up to 2 years after diagnosis (Mayo Clinic Staff, 2012).
Currently, the only way to verify the diagnosis of CJD is via an
autopsy to confirm the presence of PrPsc plaques and to observe
the formation of spongy-like holes and structures within the patient’s brain; however, doctors can accurately identify this disease
via several diagnostics. First, a physician might asses the patient
to determine if he/she portrays any of the symptoms of CJD.
Additionally, doctors may administer an Electroencephalogram
(EEG) to measure the individual’s brain’s activity. People with
CJD typically portray an abnormal pattern. Magnetic resonance
imaging (MRI) may be used to produce a high resolution image
of a person’s brain in order to determine a signs of abnormality. Another known method of testing is a spinal tap where a
physician withdraws a small amount of cerebral spinal fluid that
surrounds an individual’s brain and spinal cord. The presence of
several proteins in the CSF may be an indication of illness (Mayo
Clinic Staff, 2012). A simple blood test to detect trace amounts
of PrPsc may be an additional venue to test for CJD, but further testing is needed to determine if this is a viable method of
diagnosis (Castilla, Saa, & Soto, 2005). Furthermore, in a study
conducted by Moda et al (2014), 13 out of 14 patients with vCJD
showed signs of PrPsc in their urine samples suggesting a future
possible diagnostic for vCJD.

AD Pathophysiology
AD is a form of dementia characterized by the formation of
Amyloid-β protein (Aβ) plaques or the hyperphosphorylation of
Tau proteins along with neuron degradation in the brain. This is
accompanied with numerous cognitive relating symptoms. While
the symptoms of AD are well documented, there is much debate
over the exact mechanism in which the disease carriers out its
pathology.
One suggested mechanism is through the formation of Amyloid-β

proteins which in turn form amyloid-β plaques. The Aβ is formed
from a far larger protein called the β-Amyloid Protein Precursor
(APP). The cleavage to the Aβ form is catalyzed by the enzyme
β-CITE APP cleaving enzyme-1 (BACE1) (Small & Cappai, 2006). It
is believed that when there is an overproduction of Aβ, either via
a faulty Aβ production mechanism or a failure of the body’s clearance of the protein, Amyloid plaques are formed (Verkhratsky, et
al., 2014). These aggregations of Aβ are believed to be toxic and
are the main cause of AD.The conclusion that Aβ is involved with
the pathogenesis of AD is strongly supported by an experiment
involving APP transgenic mice. These mice contained human APP
and when induced with an amyloid disease, showed very similar pathophysiological symptoms as AD. However, within recent
years, studies have shown that Aβ plaques are not the most toxic
form of Aβ. Experiments have shown that a low molecular weight
diffusable form (non-plaque forming) of Aβ is more toxic. This
would explain why in APP transgenic mice, abnormal cognitive
symptoms are seen before Aβ plaque formation (Small & Cappai,
2006).
Another well-known hypothesis to the pathological mechanism
of AD is the formation of toxic hyperphosphorylated tau proteins.
Normal or dephosphorylated microtubule-associated protein
(MAP) tau aid in the assembly and stability of microtubule networks in neurons. If an abnormality in the MAP tau arises, there
are two other MAPs (MAP1A/B and MAP2) that can compensate;
however, when the dephosphorylated tau turns into the hyperphosphorylated form, it turns toxic. This pathological form of tau
sequesters normal tau (MAP1A/B and MAP2) while inhibiting
and disrupting microtubule structure. The neuron that has been
afflicted with this pathogenic MAP tries to dispose of the toxic
substance by synthesizing additional normal tau and by turning
the hyperphosphorylated form into an inert polymer. Eventually,
this afflicted neuron begins to degenerate at a progressively slow
pace. Aggregation of this abnormally hyperphophorylated tau has
been linked to dementia and neurofibrillary degradation. This
abnormal MAP tau appears to be the main contributor to tau
pathologies, or tauopathies, for dephosphorylation returns the
protein back to its normal functioning state. One possible reason for this abnormality may be due to a conformational change
in the MAP tau. This causes it to be a better substrate to be
phosphorylated or a worse substrate for dephosphorylation. In
either case, these conformational changes appear to cause the
pathology of AD (Iqbal, et al., 2005).
AD is typically defined via 3 diverse categories: early-onset AD
(EOAD), late-onset AD (LOAD), or early-onset familial AD
(EOFAD). With increasing age as a known risk factor, patients
who contract the disorder past the age of 65 are said to have
LOAD which resembles the majority of all AD cases. People who
are diagnosed with AD before the age of 65 is said to have EOAD
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which encompasses up to 5 percent of all cases (WebMd, 2014).
EOFAD is a form of the disorder where the onset of duress
is under 65 years of age and where the individual has one or
more of the genes associated with AD. These genes are believed
to cause the person to attain a genetic disposition towards AD
(Bird, 1999).
Genetic linkage studies have identified three different genes
associated with EOFAD. The first gene identified was the APP
gene (the gene that is responsible for APP production). It is believed that a missense mutation within this gene is a risk factor
for EOFAD. Another gene found to be correlated with AD is
PSEN1. Family studies have shown that mutations in this gene are
pathogenic. The third gene found injunction with AD is PSEN2.
Although it is far rarer than the PSEN1 mutation, it is believed
that mutations in this strand of the gene are a precursor for
pathogenesis of EOFAD. It is believed that the PSEN1 and PSEN2
genes are involved with γ-secretase, an enzyme involved with the
cleavage of APP, and a mutation in these genes cause pathology
via this pathway. The majority of EOFAD cases (81%) can be accounted for by a mutation in the PSEN1 gene, the second most
(14%) by a mutation in the APP gene, and the least (6%) associated with the PSEN2 gene (Ertekin-Taner, 2007).
Similar to EOFAD, a gene has been found to be associated with
LOAD. The Apolipoprotein (ApoE) gene codes for a protein that
transports cholesterol in the bloodstream. It is found as different
forms named ApoE ε2, ε3, and ε4. The ApoE ε3 form is the most
common form of the gene while ApoE ε2 and ε4 are less prevalent. It is believed that ApoE ε2 reduces the risks of AD and ApoE
ε4 has the contrasting effect of increasing AD pathogenesis. If
an individual attains two sets of the ApoE ε4, it greatly increases
his/her chances of AD. Unlike other known genetic mutations,
inheriting both sets of the ApoE ε4 gene does not guarantee AD
pathology (Alzheimer’s Association, 2014).
While there is no definitive method of ascertaining if an individual will contract AD, there are several disease-modifying factors
that decrease or risk factors which increase one’s probabilities of
pathology. Nam Hu et al (2013) characterizes a list of nutrients
and their risks towards AD. Antioxidants obtained in an individual’s diet were shown to reduce the risks of AD. Studies show
that maintaining a healthy level of vitamin C in a person’s diet can
have a protective effect towards AD. In regards to metals, Iron is
believed to be a risk factor for dementia while Zinc is believed
to be a cause in the delay in AD pathology. In regards to fats and
carbohydrates, while there is an assumption that these can pose
as risk factors for AD, not enough reliable evidence is available to
make a firm conclusion. Hu et al made a graph (figure 2) illustrating the effects of various everyday foods if whether or not they
increase or decrease a person’s risk towards AD.
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Figure 2
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Foods and beverages that influence the incidence of AD. Fish, vegetables,
fruits, coffee, and light-to-moderate alcohol intake are reported to
reduce AD incidence. Milk and tea are reported to influence cognition,
but their influence on AD is not clear. (Hu, et al., 2013)

Various other theories about the pathophysiology of AD contribute to our understanding of the disease. One proposed hypothesis is the degradation of the blood brain barrier (BBB). The
BBB protects the brain from various pathogens and unwanted
particles within the bloodstream. The deterioration of the BBB
can cause various proteins in the blood to enter the cerebral
spinal fluid and form plaques (Sardi, et al., 2011). Another theory
involves the metal aluminum.While the correlation is not entirely
known, it is believed that a high level of aluminum in the brain is
a cause for AD (Shcherbatykh, 2007). Further research suggests,
as mentioned by Moulton and Yang (2012), that air pollution too
plays a role in AD. While the pathogenesis of AD is multifactorial, air pollution can accelerate “age-related oxidative changes
observed in the brain”, increasing one’s risk of contracting the
disorder.
Analogous to CJD, patients who suffer from AD share many similar phenotypical symptoms. Patients have been known to exhibit emotional symptoms such as depression, anxiety, and mood
swings and cognitive symptoms such as loss of memory, difficulty
speaking, and difficulty thinking. Additionally, those who contract
AD are known to have delusions, such as paranoia, change in
sleeping patterns, and loss of inhibitions. Towards the late progression of the disorder, important skills such as reading, hobbies,
and reminiscing are lost (Mayo Clinic Staff, 2014).
Currently, there is no specific diagnostic to confirm the presence
of AD. A physician determines whether you meet the criteria of
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dementia and often they can determine if it is due to AD. Doctors
have an arsenal of diagnostic tests that they can perform to assist
in narrowing the diagnosis. One possible test is a neuropsychological test where they can identify cognitive changes. Different
types of dementia can have different cognitive patterns. A blood
test can be administered to rule out other causes of memory
loss such as vitamin deficiencies. Frequently, brain imaging is used
to identify any abnormalities within the brain. An MRI can be
used to produce a high resolution image of the brain for further
study. A computerized tomography (CT) scan uses x-rays and a
computer to generate cross-sectional images of the brain. This
can help rule out head injuries and tumors. A positron emission
tomography (PET) scan is used in conjunction with an isotope
tracer which is injected into an individual. With this machine, a
doctor can track the movement of this tracer and determine
which areas of the body are dysfunctional. All of these diagnostics
aid in the identification of AD; however, similar to CJD, the only
way to confirm illness is to perform an autopsy and to observe
plaque buildup within the brain (Mayo Clinic Staff, 2014).

Pathophysiological Comparison of AD and CJD
AD and CJD are diagnosed via their dissimilar pathological mechanism and symptoms. AD is associated with Aβ plaques and Tau
proteins and CJD with abnormal PrPsc. AD is a slow progressive
disorder with an extremely high prevalence, afflicting a third of
octogenarians, while CJD is rapidly progressing with an extremely low prevalence, afflicting one per million per year. However, no
matter the dissimilar characteristics between the two disorders,
there is evidence that there is an analogous mechanism between
the two.
It was shown in a study that PrPc prevalence affects the function of BACE1. BACE1 is a cleaving enzyme which catalyzes the
cleavage of APP to either Aβ-40 or Aβ-42, two versions of the
Aβ differing in residue length. A high expression of PrPc reduces
the severing of the APP into peptide fragments by more than 95.
This in turn reduces the secretion of Aβ-40 by 92% and Aβ-42 to
undetectable levels. The support for this conclusion arises from
the study that showed that reduced PrPc prevalence showed an
increase in Aβ-40 and Aβ-42 production. This provides strong
evidence between the correlation between AD and CJD mechanisms (Hooper & Turner, 2008).
These findings increase the probability that a slight reduction in
PrPc at a young age could cause an inconsequential accumulation
of Aβ-40 and Aβ-42 over many years, furthering the accumulation
of Aβ plaques and the onset of AD. Patients with AD showed
lower levels of PrPc in their occipital lobes with an increased
activity of BACE1.Additionally, studies show that a polymorphism
in codon 129 of the PrPc gene is a risk factor for early-onset AD.
This polymorphism changes the peptide coded in that location

to a valine or methionine causing the transconformational alteration to the PrPsc pathogenic form. This is consistent with our
assumed PrPc-BACE1 relationship. Hooper and Turner (2008)
suggest that if PrPc affects Aβ production, we can assume that
the absence of PrPc would lead to early-onset AD.
If prion proteins regulate Aβ accumulation thus preventing AD,
does Aβ regulate and/or prevent prion pathology? In an experiment involving mice infected with scrapie, a form of prion disease
in animals, it was found that in the terminal stages of the disease
there was a considerable increase in the concentration of Aβ.
Hooper and Turner comments on this that, “[i]nterestingly, the
amounts of Aβ peptides were high in scrapie-infected mice, with
a shorter disease incubation time raising the possibility that the
higher levels of Aβ might exacerbate the disease process.” If this
theory is correct that high Aβ levels contribute to the rate of
prion pathology, then this can be used as a way to slow down
the progression of these ailments. However, they point out that
we cannot rule out that the increased levels of Aβ are perhaps
a result of the scrapie pathology, as stated before, and that further study is necessary to confirm this hypothesis (Hooper &
Turner, 2008). Furthermore, Debatin et al (2008) point out that
the increased levels of Aβ could be the result of the saturation of
clearance mechanisms; since the body is preoccupied with PrPsc
maintenance, the same mechanism that also deals with Aβ accumulation becomes saturated leading to a buildup of the AD associated protein.This theory is supported by evidence that suggests
a common pathway for protein degradation of PrPsc and Aβ.
Alternatively, there are those that argue that overexpression of
PrPc increase Aβ plaque production. Lara Ordonez-Gutierrez et
al (2013) disregard the evidence that suggest that PrPc directly inhibits Aβ production by altering the activity of BACE1.They state
that most of these tests were performed in cell cultures while
studies involving older animals showed no change in the expression of BACE1 in regards to PrPc concentrations. Furthermore,
in vivo experimentation conducted by Ordonez-Gutierrez et al
(2013) discovered that older animals that expressed a high level
of PrPc expression also illustrated a high level of Aβ deposits
with no significant consequence on BACE1 levels. They speculate
that since BACE1 levels stay the same while Aβ deposit levels
increase, perhaps this surge in plaque formation is a result of
increased protein degradation and/or production via an alternate
pathway involving PrPc.
Its been suggested that a divergent reasoning for the accumulation of Aβ deposits in patients with a high PrPc expression.
They explain, given the fact an unaltered expression of PrPc is
observed during the pathology of prion disease, it is unlikely prions are the cause for Aβ accumulation in specific sCJD patients.
Being that the aggregation of misprocessed proteins is caused by
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the differences between de novo generation and its elimination, it
is a possibility that the increased levels of Aβ deposits in sCJD are
a result of a saturation of common clearance mechanisms. This
is validated by studies that show a similar clearance mechanism
is in place for both PrPsc and Aβ. Furthermore, in a group study
of sCJD patients, individuals who exhibited high levels of Aβ-42
showed little deposits of PrPsc while individuals with high levels
of PrPsc had low amounts of Aβ-42. The correlation between
Aβ-42 and PrPsc concentrations clearly indicates a shared mechanism between the two (Debatin, et al., 2008).

cortical degradation of the two disorders (Armstrong, Lantos, &
Cairns, 2005).” With all of these similarities, including the ones
mentioned earlier, it is hard to deny the correlation between
these two neurodegenerative diseases.

There are also reports discussing a few intriguing similarities
between AD and CJD. Both AD and CJD are characterized by
their peptide aggregations resulting in plaques; Aβ in AD and
PrPsc in CJD. Additionally, the authors explain how AD and CJD
can coexist in the same individual and that the Aβ and PrPsc
plaques in sporadic AD and sCJD share a similar spatial distribution throughout the brain, “suggesting a consistent pattern of
Figure 3

innervation to the spinal cord and brain (Figure 3). Cashman and
Caughey point out that replication of these prions occur in locations accessible to immunotherapy and antibody neutralization.
Due to the pathogenic pathway observed in vCJD, it is a possibility to artificially induce an autoimmune response against prions
affecting its replication. This can effectively slow down or block
pathogenesis of the disease. It has been illustrated in studies that

Villus

Possible Treatments for CJD
In persons with vCJD, it was observed that when ingested orally,
infectious prions aggregated towards gut-assisted lymphatic tissue and the spleen (Cashman & Caughey, 2004). From this location, the prions are transported via splanchnic
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Possible spread of scrapie infectivity from the gut lumen to the nervous system following oral infection (route indicated by dotted line). Soon after ingestion,
the abnormal prion isoform (PrPSc) is detected readily within Peyer’s patches on follicular dendritic cells (FDCs), within macrophages, within cells with
morphology consistent with that of M cells and within ganglia of the enteric nervous system (ENS).These observations indicate that, following uptake of
scrapie infectivity from the gut lumen, infectivity accumulates on FDCs in Peyer’s patches and subsequently spreads via the ENS to the central nervous
system. FAE, follicle-associated epithelium. © Elsevier Ltd (2000). (Cashman & Caughey, 2004)
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antibodies targeted against PrPc, cleared cells that were scrapie-infected with PrPsc in vitro. However, in vivo, antibodies targeted against normal PrPc can have adverse effects since these
cells in their non-pathogenic configuration are detrimental to
normal neurological function. The autoimmune response to PrPc
can prompt complement-dependent lysis in many cells disrupting
normal function leading to apoptosis in the brain. It is entirely
possible for an induced antibody response to reduce the immunological tolerance of PrPc with the subsequent induction of an
autoimmune disease (Cashman & Caughey, 2004).
Often when a protein misfolds causing pathology, a sidechain
of peptides that originally was sequestered within the molecule
becomes exposed providing a means of distinguishing between
pathogenic and non-pathogenic conformational isotopes. This
specificity can aid in devising a means of targeting PrPsc alone
without affecting the normal PrPc. The therapeutic potential of
this approach is immense with the benefit of leaving non-pathogenic proteins unharmed (Paramithiotis, et al., 2003).
There are several chemical inhibitors of CJD progression in vitro.
Cyclic tetrapyrroles have been shown to slow the progression of
scrapie in mice; however, this was only if treatment began immediately after infection due to its inability to cross the BBB. Other
tetrapyrroles that do cross the BBB could prove to be efficacious
further in the stages of infection. It is believed that cyclic tetrapyrroles inhibit PrPsc by direct interaction with the protein.
Polyene antibiotics and dimethlysulphoxide are also thought to
inhibit PrPsc pathology. Polyene antibiotics target prions while
dimethlysulphoxide helps reduce accumulations and excretion of
PrPsc. Unfortunately, no chemotherapeutic drug has been shown
to significantly alleviate the pathology of CJD once clinical symptoms are present (Cashman & Caughey, 2004).
Several other therapies have been suggested for CJD treatment.
One is through gene therapy via a lentiviral vector-mediated
RNA interference (RNAi). A lentivirus is a genus of viruses that
can be modified to implement specific genes within a host’s genome or silence others. This is achieved through short hairpin
RNAs (shRNAs) that can silence select genes. A study conducted
with scrapie-infected neuronal cells that involved shRNAs that
suppressed the PrPc gene, PRNP, showed an efficient suppression
of PrPsc aggregation. Mice infected with lentivirues with shRNAs
showed a reduced expression of PrPc and an extended lifespan
of those infected with scrapie. Although further testing needs to
be done, a lentiviral vector-mediated RNAi appears to be a valid
approach for the treatment of CJD (Pfeifer, et al., 2006). However,
reducing PrPc expression may hinder CJD pathogenesis but it
may also contribute to various adverse effects. additional research will need to be conducted to attain a viable solution to
these concerns.

Another suggested therapy is by the use of antihistamines, specifically astemizole. Experiments involving astemizole indicated that
it prolonged the lifespan of scrapie-infected mice. Additionally,
astemizole has the capabilities of crossing the BBB making it a
favorable drug for the treatment of CJD. Except for a rare case of
heart arrhythmia, astemizole is an over-the-counter drug that is
relatively safe in recommended doses. It is theorized that astemizole’s antiprion properties arises from its activity on autophagy,
which is the degradation and recycling of cells and proteins. It
is suggested that individuals containing mutations in the PRNP
gene and who are genetically susceptible to CJD should take astemizole regularly as a preventative measure against disease. The
effects of astemizole on autophagy could provide new methods
for treating other neurodegenerative diseases (Karapetyan, et al.,
2013).

CJD treatments vs AD pathology
Can several potential treatments for CJD be administered or
modified to treat AD? AD is associated with the accumulation of
abnormal proteins (Aβ and/or Tau proteins). It is possible to target these molecules via an induced autoimmune response such
as that observed in CJD treatments (Cashman & Caughey, 2004).
However, this can initiate a negative cascade in which the body
targets normal functioning Aβ or Tau proteins resulting in cell
lysis and the reduced immunological tolerance towards normal
cells causing autoimmune disease.
Abnormal proteins are often accompanied by the exposure of a
previously sequestered side chain. This side chain can be used to
target pathogenic proteins alone without interfering with normal function. These findings can be applied to AD in treating Aβ
and Tau fibril accumulations. Although further experimentation is
needed to produce a safe autoimmune induced treatment, this
can be a viable method to combat AD pathology (Paramithiotis,
et al., 2003).
Lentivector-mediated RNAi can be used to treat AD as well.
ShRNAs that repress specific gene expression could be used to
suppress a faulty gene that causes pathology. For instance, if an
individual has two genes coding for a molecule involved in the
pathogenic AD pathway with one of the genes corrupted and the
other in its normal function, shRNAs can be utilized to silence
the faulty gene’s expression without affecting the normal one.
However, Lentivector-mediated RNAis can suppress the function
of both normal and faulty genes causing unwanted adverse effects
(Pfeifer, et al., 2006). This prototype treatment for CJD can ultimately be utilized to treat other disorders such as AD.
Direct modification of PrPsc/PrPc levels is another option for
AD treatment.With a theorized mechanism correlation between
PrPc and Aβ proteins, it is possible to indirectly treat AD by
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inducing prion production. For instance, Hooper and Turner believe that PrPc regulates Aβ levels by inhibiting enzyme catalyzed
cleavage of APP to Aβ-40 and Aβ-42. The greater the PrPc levels,
the lower the levels of Aβ in the body. If a patient has AD due
to high levels of Aβ, according to Hooper and Turner (2008), it
should be possible to reduce these levels by increasing expression of PrPc production (see figure 4). Ordonez-Gutierrez et al
(2013) argue that increased levels of PrPc increase Aβ plaque
formation. This suggests that reducing PrPc concentrations is the
viable method in treating Aβ aggregations in AD. More data has
to be obtained to procure the exact mechanism between PrPc
and Aβ. It seems that both Hooper and Turner and OrdonezGuiterrez et al agree that a related mechanism exists between
the two proteins, it is the effect one has on the either that is
in question. Either way, understanding how these two molecules
interact can be important in treating either of these two neurodegenerative disorders. Prion diseases can offer scientists a
prototype on the processes of other neurological disorders such
as AD (Cashman & Caughey, 2004).

Possible treatments for AD
Currently, AD patients are treated with two different types of
drugs, either acetylcholinesterase inhibitors or memantine.
Acetylcholinesterase inhibitors act by increasing cell-to-cell
communication chemical levels that were diminished during AD
onset. This is accomplished by inhibiting enzymes that facilitate
the breakdown of acetylcholine, a neurotransmitter found within the brain. Progression of symptoms is usually maintained for
Figure 4
Gene defect

Environmental
trigger
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Prion protein
Amyloid β peptide accumulation

Amyloid plaque

Dementia

Alzheimer’s brain
The role of the prion protein in Alzheimer’s disease prevention: In the amyloid
cascade hypothesis of AD, a genetic mutation (for example, in the genes
encoding APP or the presenilins), ageing or some other environmental trigger
(e.g. oxidative stress) causes an accumulation of the neurotoxic Ab peptide,
which aggregates to form the characteristic amyloid (senile) plaques found
post-mortem in the brains of AD patients.Through mechanisms that are
poorly understood, the increased levels of Ab peptides, particularly oligomeric
and fibrillar forms, cause neuronal cell death and dementia. The normal
cellular form of the prion protein, through inhibiting the production of the
Ab peptide, might help to prevent the development of AD (Hooper & Turner,
2008).
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a time before AD pathology continues to worsen. Memantine
works via a different pathway within the brain, slowing the development of symptoms relating to AD. The mode of action for
memantine is to target and inhibit NMDA receptors which has
shown to improve cognitive function compared to a placebo.
Unfortunately, medication only forestalls pathology since there is
no cure for AD (Gotz, Ittner, & Ittner, 2012) (Eubanks, et al., 2006)
(Mayo Clinic Staff, 2014).
Research into the immunization against Aβ showed promising
results. Mice immunized with Aβ-42 showed reduced Aβ burden
and preserved cognitive function. In an interrupted clinical trial,
patients who were injected with one, two, or three immunizations of Aβ-42 showed decreased levels of tau proteins with
postmortem reports of diminished Aβ in the neocortex.The trial
was interrupted because 6% of the patients developed meningoencephalitis (Gilman, et al., 2005). Using natural anti- Aβ antibodies derived from healthy humans may provide a better method
in reducing adverse effects such as encephalitis in patients (Sardi,
et al., 2011). Although the clinical trial was suspended, immunotherapy seems to be a viable method in treating AD (Gilman, et
al., 2005).
In a recent pharmaceutical study, a monoclonal antibody aimed
at Aβ named Bapineuzumab was intravenously administered for
78 weeks. It was found that there was a diminished phosphorylated tau along with a reduced accumulation of Aβ in the brain
of AD individuals carrying the pro-pathological gene, ApoE ε4.
These findings show promise in the treatment of AD through reductions of plaque buildup. Interestingly, these reductions of the
disease-inducing molecules were not able to forestall the rate of
pathological progression in the disorder. One suggested hypothesis is that Bapineuzumab was administered too far along in the
AD pathology. To remedy this concern, the drug would have to
be administered before the appearance of clinical symptoms.This
poses an issue since it is extremely difficult to diagnose a patient
before symptoms appear; however, it may be able aid those who
are high risk for AD. Another hypothesis is the actual pharmaceutical mechanism of the drug. As of yet, Bapineuzumab does
not target phosphorylated tau that aggregated into neurofibrillary tangles, another hallmark of AD (Cedernaes, et al., 2014).
While further study is needed to improve the efficaciousness of
antibodies against AD, immunotherapies are strong contenders in
discovering a feasible treatment for neurodegenerative diseases.
Non-steroidal anti-inflammatory drugs (NSAIDs) have been
shown to be a preventative measure for AD. There are reports
that suggest that BBB degradation plays a central role in AD.
As the BBB degrades, many previously unwanted molecules
cross into the fluid surrounding the brain possibly eliciting a response of inflammation. Inflammation can further increase the
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permeability of the BBB allowing circulating Aβ to enter the brain
where it can start a degenerative and inflammatory process.
NSAIDs are drugs that reduce pro-inflammatory responses in
the body. Studies have shown that patients who were medicated
with NSAIDs over a long period of time exhibited a reduced
incidence of AD. This indicates the presence of pro-inflammatory
molecules in the pathology of AD (Sardi, et al., 2011).

may be an alternative route in AD treatment. Studies involving
an induced increase in metabolic activity by administering a concoction of glucose and several Krebs cycle intermediates into
patients showed an increase in cognitive function with less neurodegeneration. Improving a deficient mitochondrial spiral may
prove to be effective in treating AD (Blass, 2001).

AD treatments vs CJD pathology
Many therapies for AD focus on ameliorating Aβ levels in the
brain without much focus on tau proteins concentrations.
Treatments aimed at pathogenic tau proteins produced reasonable results. Abnormal tau proteins are phosphorylated versions
of the normal tau form. One method of treatment is to inhibit
this phosphorylation. Administered lithium chloride inhibited glycogen synthase kinase-3, an enzyme that catalyzes the transfer
of a phosphate group onto other molecules, and reduces the
levels of hyperphosphorylated tau, insoluble tau, and behavioral
impairment in various mice models. Inhibition of other kinases
also showed promising results. Furthermore, immunization with a
tau phospho-peptide prevented pathology in tau transgenic models with no apparent adverse effects (Gotz, et al,, 2012). With the
promise of tau directed therapies, it is worthwhile to formulate
treatments involving both Aβ in conjunction with tau proteins.

With AD and CJD sharing many pathological pathways, it seems it
may be possible to treat CJD via techniques previously reserved
for AD. Acetylcholinesterase inhibitors that reduce the enzymatic degradation of acetylcholine perhaps can be used to alleviate
symptoms of dementia found in patients with CJD (Cummings,
2000). With the increased levels of the neurotransmitter acetylcholine in vivo, there can be an increased level of cell-to-cell
communications within the brain possibly easing several cognitive
symptoms. However, inhibition of this enzyme is most likely not a
viable method of treatment for there is little research conducted
on the effects of acetylcholinesterase inhibitors on CJD. There is
some evidence that memamtine, another drug used to treat AD,
Figure 5
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The active component of marijuana, ∆9-tetrahydrocannabinol
(THC), appears to also be an efficacious and viable method in
the treatment of AD. THC competitively inhibits the enzymatic protein acetylcholinesterase which catalyses the breakdown
of acetylcholine. It is believed that acetylcholinesterase is a key
component in the pathological progression of AD by inducing
Aβ plaque formation. THC effectively inhibits this enzyme, reducing the degradation of acetylcholine transmitters in the brain
while simultaneously diminishing Aβ plaque formation. This treats
both the progression and the symptoms of the disease. THC is
a superior inhibitor of acetylcholinesterase as opposed to other
acetylcholinesterase inhibiters that are currently used to treat
AD. Additionally, THC appeared more effective with only half the
dosage compared to these other medications. (Eubanks, et al.,
2006).

has some inhibitory effects towards PrPsc (Muller, et al., 1993).

The treatment of metabolic deficiency is another suggested alternative in treating AD. An abnormality in the energy metabolism, calcium metabolism, or free radical pathways showed to
contribute to deficiency within the other two metabolic routes
creating a “mitochondrial spiral”. This spiral forms a negative cascade effect where the defects of one metabolic pathway continue
to degrade other pathways which in turn further damage the
original faulty pathway (see figure 5). It is thought that mitochondrial spiral causes abnormities in the metabolism of the APP
and the segments of Aβ it produces. It may also be a proximate
reason for clinical debilities found in AD. Ameliorating the spiral

Immunizations for CJD have been thought of as a method of
treatment as well. Similar to AD, antibodies targeted against proteins associated with CJD have showed some promising results.
However, being that adverse effects were found with immunizations, research has to be done before it is safe for public use as
a treatment for CJD (Cashman & Caughey, 2004). NSIADs have
been suggested as a treatment for CJD. Inflammation has been
associated with both AD and CJD. In contrast to AD, there is
little data available on the effectiveness of NSAIDs on CJD. In
vivo studies showed that NSAIDs may have some effect on prion
pathology, nevertheless, experiments using patients showed

Energy
insufficiency
Ca++
The mitochondrial spiral. Impairments of energy metabolism, alterations in
cellular calcium homeostasis, and excess free radicals (ROS) interact with
each other in mitochondria; inducing any one of them leads to abnormalities
in the other two.The interaction can set up a deleterious, downward cycle
(Blass, 2001).
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disappointing results. It is possible that the NSAIDs were given
too late in the disease pathogenesis. Further study is needed to
determine if antiinflammatory drugs are a suitable treatment for
CJD (Eikelenboom, et al., 2002).
Treatment of the “mitochondrial spiral” may play a role with individuals with CJD. In regards to AD, it was found that a deficiency
in one of three different metabolic pathways can cause deficits
in the other two creating a mitochondrial spiral. Attempts to
alleviate the stress on this spiral showed to improve cognitive
symptoms in patients (Blass, 2001). In CJD, some studies show
oxidative abnormalities plays a role in pathogenesis (Petersen, et
al.).This can cause defects in one of the three metabolic pathways
mentioned earlier. Alleviating these deficiencies may be a viable
venue of treatment. It should be mentioned that other studies
found no role of oxidative stress in CJD (Bleich, et al., 2000).
Further study is needed on the topic to fully understand the
effects of the mitochondrial spiral on disease pathogenesis.
It was suggested that it is possible that Aβ contributes to CJD
pathology. It has been hypothesized that Aβ exacerbated the disease process by possibly accelerating the pathology (Hooper &
Turner, 2008). If this hypothesis proved to be correct, any treatment formulated towards AD can in turn be prescribed for the
mitigation and delaying of symptoms in CJD. Additionally, it was
found that the other protein linked with AD, tau proteins, were
associated with prion pathology (Han, et al., 2006). As additional
experimentation is required to determine the exact impact of
one protein on the other, treatments made to diminish tau pathology may ameliorate symptoms of CJD. These hypothesized
venues of remedy will not cure prion pathology but can most
likely hinder CJD neurodegenerative impacts on the brain. The
correlation between these two diseases is too strong to suggest
otherwise. Furthering research into understanding CJD is a viable method of ascertaining a feasible treatment for the growing
epidemic that is AD.

Conclusion
AD and CJD are both neurodegenerative disorders that share a
common pathophysiological mechanism. PrPc and Aβ, proteins associated with pathology in CJD and AD respectively, are believed
to interact with each other. There is a slight debate whether they
interact directly by contact or indirectly by affecting enzymatic
proteins, such as BACE1. Additionally, there is an argument how
they influence each other in regards to inhibiting/promoting pathology; for example, does PrPc induce or inhibit Aβ aggregations
that cause pathology? Either way, there is a strong correlation of
pathologies that most scientists agree with. It is this connection
that helped researchers discover new and creative treatments
for AD and CJD. Treatments that were previously reserved for
either disease are now being tested against the other. This is
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enhancing the understanding of the mechanisms of each ailment,
bringing researchers one step closer to discovering a cure for
both neurodegenerative diseases. Perhaps, discovering the means
of pathologies for AD and CJD will lead to cures for many other
forms of dementia.

Abbreviations
AD – Alzheimer’s Disease
ApoE - Apolipoprotein
APP – β-Amyloid precursor protein
Aβ – Amyloid-β protein found in excess amounts in patients with
AD
BACE1 - β-CITE APP Cleaving Enzyme-1
BBB - Blood Brain Barrier
CJD – Creutzfeldt – Jakob Disease
EOFAD – Early-Onset Familial Alzheimer’s Disease
LOAD – Late-Onset Alzheimer’s Disease
MAP - Microtubule-Associated Protein
NSAIDs - Non-steroidal anti-inflammatory drugs
POPG - 1-Palmitoyl-2-oleoyl-phosphatidylglycerol
PrPc – The normal form of a prion protein
PrPsc – the abnormal variant of a prion protein associated with
CJD
RNAi - RNA interference
sCJD – Sporadic Creutzfeldt-Jakob Disease
shRNAs - Short Hairpin RNAs
THC - ∆9-Tetrahydrocannabinol, the active component in
marijuana
TSE - Transmissible spongiform encephalopathies
vCJD – Variant Creutzfeldt-Jakob Disease
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